Century Therapeutics Presents Nonclinical Data for CNTY-813
Century Therapeutics presented nonclinical data for CNTY-813, demonstrating sustained glycemic control, scalable manufacturing consistency, and immune-evasive function. The IND is on track for Q4 2026, with an initial clinical readout expected in the second half of 2027.